Patents by Inventor Daniel Lohse

Daniel Lohse has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bi-aryl meta-pyrimidine inhibitors of kinases
    Publication number: 20070259904
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: April 26, 2007
    Publication date: November 8, 2007
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved Pathak, Daniel Lohse, John Hood, Richard Soll
  • Bi-aryl meta-pyrimidine inhibitors of kinases
    Publication number: 20070191405
    Abstract: The invention provides biaryl meta-pyrimidine compounds having the general structure (A). The pyrimidine compounds of the invention are capable of inhibiting kinases, such as members of the Jak kinase family, and various other specific receptor and non-receptor kinases.
    Type: Application
    Filed: October 26, 2006
    Publication date: August 16, 2007
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Chi Mak, Jianguo Cao, Joel Renick, Andrew McPherson, Binqi Zeng, Ved Pathak, Daniel Lohse, John Hood, Richard Soll
  • Thiazole inhibitors targeting resistant kinase mutations
    Publication number: 20070161645
    Abstract: A compound is provided, having the general structure (A): wherein A is an aryl or heteroaryl group, Y is a hydrophbic linking moiety, and L is a substitutent. The compound (A) can be used for treatment of various angiogenic-associated or hematologic disorders, such as myeloproliferative disorders in patients who do not respond to kinase-inhibition therapy that comprises administering currently used medications.
    Type: Application
    Filed: October 31, 2006
    Publication date: July 12, 2007
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Jianguo Cao, Binqi Zeng, Chi Mak, Andrew McPherson, Joel Renick, Ved Pathak, Chun Chow, Moorthy Palanki, Richard Soll, Daniel Lohse, John Hood, Elena Dneprovskaia
  • Six membered heteroaromatic inhibitors targeting resistant kinase mutations
    Publication number: 20070149508
    Abstract: A compound is provided, having the general structure (A): wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved medications.
    Type: Application
    Filed: October 31, 2006
    Publication date: June 28, 2007
    Applicant: TargeGen, Inc.
    Inventors: Glenn Noronha, Jianguo Cao, Binqi Zeng, Chi Mak, Andrew McPherson, Joel Renick, Ved Pathak, Chun Chow, Moorthy Palanki, Richard Soll, Daniel Lohse, John Hood, Elena Dneprovskaia
  • Small molecule thienopyrimidine-based protein tyrosine kinase inhibitors
    Publication number: 20060004002
    Abstract: Various thienopyrimidine-based analog compounds are able to selectively inhibit the Src family of tyrosine kinases. These compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.
    Type: Application
    Filed: July 2, 2004
    Publication date: January 5, 2006
    Inventors: Thomas Thrash, Larry Cabell, Daniel Lohse, Raymond Budde